192 related articles for article (PubMed ID: 31094181)
1. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
Maevskaya MV; Ivashkin VT; Ivashkin KV; Lunkov VD; Liusina EO; Zozula VN; Leshchenko VI
Ter Arkh; 2019 Mar; 91(2):109-117. PubMed ID: 31094181
[TBL] [Abstract][Full Text] [Related]
2. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
Beaton MD; Al-Judaibi B
Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632
[No Abstract] [Full Text] [Related]
3. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Alawad AS; Levy C
Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
[No Abstract] [Full Text] [Related]
4. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
Carr RM; Reid AE
Curr Atheroscler Rep; 2015 Apr; 17(4):500. PubMed ID: 25690590
[TBL] [Abstract][Full Text] [Related]
5. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
[TBL] [Abstract][Full Text] [Related]
6. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
7. [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Barabanchyk OV; Svintsits'kyĭ AS; Kozak NP
Lik Sprava; 2014 Nov; (11):48-53. PubMed ID: 25528832
[TBL] [Abstract][Full Text] [Related]
8. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
10. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial.
Oh B; Choi WS; Park SB; Cho B; Yang YJ; Lee ES; Lee JH
Int J Clin Pract; 2016 Apr; 70(4):302-11. PubMed ID: 26997458
[TBL] [Abstract][Full Text] [Related]
12. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.
El Hadi H; Di Vincenzo A; Vettor R; Rossato M
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064058
[TBL] [Abstract][Full Text] [Related]
13. Review article: Drug therapy for non-alcoholic fatty liver disease.
Comar KM; Sterling RK
Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic steato-hepatitis.
Chawla Y; Amrapurkar D
Trop Gastroenterol; 2002; 23(4):186-8. PubMed ID: 12833707
[No Abstract] [Full Text] [Related]
15. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
16. [CURRENT ISSUES IN THE CHOICE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME AND RELATED NON-ALCOHOLIC FATTY LIVER DISEASE].
Morozova TE; Rykova SM; Shmarova DG
Eksp Klin Gastroenterol; 2016; (6):95-9. PubMed ID: 30280852
[TBL] [Abstract][Full Text] [Related]
17. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.
Orlando R; Azzalini L; Orando S; Lirussi F
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD005160. PubMed ID: 32645206
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of alcoholic and non-alcoholic fatty liver].
Stremmel W; Blechacz B; Herrmann T; Rost D; Mueller S
Internist (Berl); 2001 Dec; 42(12):1641-2, 1645-50. PubMed ID: 11793603
[No Abstract] [Full Text] [Related]
20. [Experience in treatment of chronic toxic hepatitis by ursodeoxicholic acid].
Agzamova GS
Med Tr Prom Ekol; 2001; (1):39-42. PubMed ID: 11221110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
